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1. Introduction 
The basic goal of any treatment is to cure the sign and 
symptom of disorders and provide comfort to the patients. Tablets and 
capsules are unsuitable for administering with high dose of active 
pharmaceutical ingredient and since individual large dose is difficult to 
swallow or require the administration of several tablets or capsule at a 
time, making it less patient compliant. Also chewable tablets are also not 
ideal with pediatric and geriatric patients due to need of chewing, poor 
taste masking and lack of control release possibility. Oral drug delivery is 
most preferred route of drug delivery [1, 2]. Oral liquid suspensions are 
majorly designed for the patients with difficulty in swallowing. Sustained 
release dosage forms aimed at controlling the rate of release as well as 
maintaining desire drug levels in the blood for long duration of time. An 
oral suspension could be the best suitable dosage form for geriatric and 
pediatric patients. They include improvement of the rate and extent of 
drug absorption, higher patient compliance, reduction of side effects and 
taste masking of bitter drug [3, 4]. There are several of approaches to 
design and development of sustained release suspension of variety of 
drugs. Formulation of sustained release suspension will be benefited to 
avoid fluctuations in blood drug plasma concentration and gives its 
action for an entire period of time [5, 6].  
Linezolid is poorly water soluble drug (3 mg/ml) of BCS class 
II. Linezolid is an neutral drug and it has a short half-life, due to which it 
requires frequent administration to maintain the therapeutic effect for a 
long period of time  and also  it is not sustained to own due to short half-
life, so sustained release formulation are formulated. Linezolid has low 
plasma protein binding (approximately 31%, but highly variable) and 
apparent volume of distribution at steady state of around 40-50 liters. 
Peak serum concentrations are reached up to one hour after 
administration of drug. Linezolid is readily distributed to all tissues in the 
body apart from bone matrix and white adipose tissue.  
 
2. Materials and methods 
2.1 Materials 
Linezolid was obtained as a gift sample from Cadila healthcare 
Ltd., Ahmadabad, India. Eudragit RS100 and Eudragit RL100 were 
obtained as gift sample from Evonic Degussa, India. Ethyl cellulose, 
Xanthan gum, Acacia and Gaur gum were obtained as gift sample from 
Finar chemicals, Mumbai, India. All others reagents and chemicals used 
were of analytical reagent grade. 
 
 
 
Abstract 
The purpose of this research work was to design and evaluation of a stable 
reconstitutable Sustained release suspension for pediatric and geriatric patients using spray 
drying techniques. Linezolid is the drug of choice in treatment of infections caused by multi-
resistant bacteria. The microcapsules were prepared by spray drying method. Drug loaded 
microcapsule were prepared using Eudragit RS and RL100 and ethyl cellulose in three different 
polymer ratio. The influence of the drug to polymer ratio and feed flow rate was studied on the 
properties of microcapsule using a 32factorial design. The drug to polymer ratio (X1) and feed flow 
rate (X2) were selected as independent variable and percentage yield, particle size, encapsulation 
efficiency, Q6, Q8, t90% were selected as dependent variables. Accelerator stability study of 
reconstitutable SR suspension was performed as per ICH guideline. From the study of the 
preliminary and factorial batches, all the physical characteristics of microcapsules are in 
acceptable range. Results was clearly indicated that drug to polymer ratio and feed flow rate had 
significant influence on percentage yield, particle size, encapsulation efficiency, Q6, Q8, t90, Diffusion 
coefficient (n) and Release rate constant (k). Form the study, the optimized formulation (S3) 
showed 99.12% drug release at the end of 12 hrs with drug to polymer ratio (1:1.3) and feed flow 
rate (5 ml/min) respectively for obtaining the higher percentage of yield, maximum encapsulation 
efficiency, Particle size of microcapsules which is found to be 87.82%, 99.07% and 16.06µm 
consequently. SEM showed that microcapsules were spherical with smooth surface. The 
dissolution profile of optimize batch exhibits similarity factor (f2=82.35) and dissimilarity factor 
(f1=2.90) with theoretical release profile of linezolid. Microcapsule prepared with 1:1.3 drug to 
polymer ratio were selected for SR suspension formulations since they have higher loading 
efficiency and suitable micromeritic properties to disperse in aqueous medium. Results reported 
the release profiles of suspension prepared from microcapsules had no significant difference 
(P>0.05) was observed in CPR for sustained release suspension on 1day and after 15days which 
indicates the suspension stability. Results clearly revealed that drug release studies of SR 
suspension formulation did not show any statistically significant differences (P>0.05) from the 
properties of microcapsule alone. 
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2.2 Methods  
2.2.1 Preparation of Microcapsules and Reconstitutable Sustained 
Release Suspension Microcapsules 
Microcapsules were prepared by spray drying technique using 
varying ratios of drug and polymers in 1:1, 1:2 and 1:3 ratios like 
(Eudragit RS100, Eudragit RL100 and Ethyl cellulose) and the effects of 
various polymers on release of drug from microcapsules were studied by 
constant feed flow rate 5ml/min. Preliminary study formulas of all 
different microcapsule formulation of linezolid are listed in Table 1. 
Reconstitutable SR suspensions were prepared using optimize 
batch of microcapsules mixed with various suspending agent (xanthan 
gum, acacia, gaur gum), Sweetener (sucrose), preservative (Na benzoate), 
buffering agent (citric acid) and flavoring agent (cherry). Optimize batch 
formulas of all different reconstitutable sustained release suspension 
formulations of linezolid are listed in Table 2. 
 
Table 1: Microcapsules Formulations of Linezolid (F1-F9) 
Batch code Polymer Polymer ratio Feed flow rate Solvent 
F1 Eudragit RS100 1:1 5 ml/min Dichloromethane 
F2 Eudragit RS100 1:2 5 ml/min Dichloromethane 
F3 Eudragit RS100 1:3 5 ml/min Dichloromethane 
F4 Eudragit RL100 1:1 5 ml/min Dichloromethane 
F5 Eudragit RL100 1:2 5 ml/min Dichloromethane 
F6 Eudragit RL100 1:3 5 ml/min Dichloromethane 
F7 Ethyl Cellulose 1:1 5 ml/min Dichloromethane 
F8 Ethyl Cellulose 1:2 5 ml/min Dichloromethane 
F9 Ethyl Cellulose 1:3 5 ml/min Dichloromethane 
 
Table 2: Composition of reconstitutable sustained release suspension formulations 
Ingredient N1 N2 N3 N4 N5 N6 N7 N8 N9 
Microcapsule 1380 1380 1380 1380 1380 1380 1380 1380 1380 
Xanthan gum 30 40 50 - - - - - - 
Gaur gum - - - 30 40 50 - - - 
Acacia - - - - - - 30 40 50 
Sucrose 400 400 400 400 400 400 400 400 400 
Sodium benzoate (preservatives) 3 3 3 3 3 3 3 3 3 
Citric acid (buffering agent) 3 3 3 3 3 3 3 3 3 
Cherry flavour q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
* The entire ingredient is taken in the mg and in % w/w of microcapsule 
* 1380 mg microcapsule contain equivalent to 600 mg of linezolid 
 
2.2.2 Optimization of Variable Using Factorial Design 
A 32 randomized full factorial design was used in the present 
study. In this design, 2 factors were evaluated; each 3 levels and 
experimental trials were performed for all 9 possible combinations (Table 
5). The polymer concentration (X1) and feed flow rate (X2) were chosen 
as independent variable in 32 full factorial design (Table 4), while 
percentage yield, particle size and encapsulation efficiency were taken as 
dependent variables (Table 3). 
A 32 randomized full factorial design was used in development 
of dosage form. A statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the response. 
Y=b0+b1X1+b2X2+b11X1X1+b22X2X2+b12X1X2 
Where, 
Y = dependent variable 
b0 = arithmetic mean response of the 9 runs 
bi =estimated coefficients for the factor Xi 
The main effect (X1andX2) represents the average result of 
changing one factor at a time from its low to high value. The interaction 
term (X1X2) shows how the response changes when two factors are 
change simultaneously. The polynomial terms (X1X1, X2X2) are included to 
investigate nonlinearity [7]. 
 
Table 3: List of Independent Variables and Dependent Variables 
Independent Variables: 
Polymer Ratio (X1) Feed flow rate (X2) 
Dependent Variables: 
% yield Time required for 90% drug 
release (t90) 
Microencapsulation efficiency 
(%) 
% drug release after 6 hrs (Q6) 
Mean Particle size Diffusion coefficient (n) 
Time required for 50% drug 
release (t50) 
Release rate constant (k) 
 
Table 4: Coded value and independent variable 
Coded value Selection of level of independent variable 
Coded value X1 (polymer ratio) X2 (feed flow rate) 
-1 1:1.1 5 
0 1:1.2 10 
+ 1:1.3 15 
* X1=Polymer ratio                  *X2=Feed flow rate 
 
 
Table 5: Coded value and uncoded value 
Sr. No. Coded value Uncoded value 
X1 X2 X1 X2 
1 -1 -1 1:1.1 5 
2  0 -1 1:1.2 5 
3 +1 -1 1:1.3 5 
4  -1 0 1:1.1 10 
5   0 0 1:1.2 10 
6 +1 0 1:1.3 10 
7  -1 +1 1:1.1 15 
8   0 +1 1:1.2 15 
9 +1 +1 1:1.3 15 
 
2.2.3 Validation of Experimental Design 
2.2.3.1 Percentage relative error or bias 
To assess the reliability of the model, a comparison between 
the experimental and predicted values of the responses is also presented 
in terms of % bias (relative error %). The formula for calculation of % 
bias or % relative error is as follows: 
% Bias =
predicted value− actual value
predicted value
× 100 
It is calculated from the equation 
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Y=b0+b1X1+b2X2+b11X1X1+b22X2X2+b12X1X2 
Where, 
Y= Y is the predicted response 
b0= arithmetic mean response of the 9 runs 
bi=estimated coefficients for the factor Xi 
Predicted responses are calculated from the above formula 
with the help of X1 and X2 variable from table no. 4.16 and actual 
response are taken from the experimental work. 
2.2.3.2 Check point batch 
 Polynomial equations were generated using Statistica 8.0 for 
selected responses like % yield, particle size, encapsulation efficiency, 
Q6.Q8, t90%, Exponential constant (n) and release rate constant (k) .The 
generated polynominal equations were further reduced on the basis of 
significant terms obtained by applying ANOVA. The design was validated 
by preparing an extra check point formulation. The predicted values for 
response were determined on the basis of respective polynomial 
equations whereas the experimental values were determined by 
evaluating formulation for dependent variable. The predicted and 
experimental values of responses were compared for statistical 
significance using paired t –test [8, 9]. 
2.2.3.3 Physical Characterization of Microcapsule 
The prepared microcapsules were evaluated for the flow 
properties, such as loose bulk density, tapped density, carr’s index, 
Hausner ratio and angle of repose [10-13]. 
2.2.4 Evaluation of Microcapsule 
2.2.4.1 Mean Particle size determination by microscopic method 
Binocular microscope was used for the particle size at 100 
magnifications Particle size observed in ocular scale (µm) [14]. 
2.2.4.2 Particle size and shape by Scanning Electron microscopy 
The surface topography of the microcapsule was investigated 
by SEM. Scanning electron microscopy (SEM) photographs were taken 
using a scanning electron microscope (JSM-5610, Japan) at room 
temperature. Samples were fixed on a scanning electron microscope 
sample holder with a double-sided adhesive tape and coated with a layer 
of gold of 1.5 × 10–10 m for 2 min using a sputter coater (Edwards 3-150 
Å, England) in a vacuum of 30.4 kPa of argon gas. Photographs were 
observed for morphological characteristics and to confirm the spherical 
nature of microcapsule [15]. 
2.2.4.3 Morphological studies of microcapsule by simple binocular 
microscope 
Morphological characteristic of microcapsule of the 
preliminary and factorial batches are determined by the simple binocular 
microscope. Spray dried microcapsule are taken on the glass slide and 
determine the morphological character of the microcapsule under the 
simple binocular microscope. Samples of spray dried microcapsule were 
selected randomly. 
2.2.4.4 Percentage yield 
The percentage of production yield (wt/wt) was calculated 
from the weight of dried microcapsule (W1) recovered from each of 
batches and the sum of the initial dry weight of starting materials (W2). 
The formula for calculation of percentage yield is as follows [16]. 
% Yield =
Weight of dried microcapsules  W1 
total Weight of drug and polymer  W2 
× 100 
2.2.4.5 Drug loading 
Drug loading are calculated of the microcapsule by weighting 
the microcapsule after spray drying with polymer and drug to the total 
quantity of drug taken before spray drying [16]. 
Drug loading =
Weight of drug loaded in microcapsule
Total weight of microcapsule 
× 100 
2.2.4.6 Encapsulation efficiency 
To estimate linezolid content, drug loaded microcapsule were 
weighted and crushed properly in mortar and pestle. Briefly 200 mg of 
each batch of linezolid-loaded microcapsule were crushed and then 
dissolved in 100 ml of phosphate buffer 7.2 pH. The above solution was 
kept on sonicator for 3 to 4 hours to get maximum drug released from 
microcapsule into solution. Then phosphate buffer containing drug was 
filtered through whattman filter paper to remove any polymer debris. 
The clear solution obtained was analyzed using UV spectrophotometer at 
ƛmax value of 251 nm using pure phosphate buffer as blank [17]. The % 
Encapsulation efficiency of linezolid microcapsule was calculated using 
formula as follows  
% Encapsulation efficiency =
% Drug loading 
% Theoretical loading
× 100 
2.2.4.7 Drug Content Uniformity 
Weight accurately the 200mg microcapsule which contains 
100mg equivalent weight of linezolid and then transferred to 100ml of 7.2 
pH Phosphate Buffer containing volumetric flask and kept on sonicator for 
3-4 hours to get maximum drug release from microcapsule into solution. 
The solution was analyzed at 251nm using double beam UV-Visible 
spectrophotometer after suitable dilution. The content of drug was 
calculated from calibration curve [18]. 
2.2.4.8 In-vitro drug release study 
The In-vitro drug release was performed using USP 24 type II 
paddle apparatus using 700 ml of 0.1 N HC1 at 50 rpm at 37±0.5°C for 
first two hours. The samples were withdrawn at predetermined time 
intervals for period of 2 hr and replaced with the fresh medium. After 2 
hours that add the 200 ml solution of tri-sodium phosphate to replace the 
pH 1.2 to 7.2 and sample are withdrawn at predetermined time intervals 
for remaining 10 hrs. The samples were filtered through whattman filter 
paper; suitably diluted and analyzed at 251nm using double beam UV-
Visible spectrophotometer. The content of drug was calculated using 
calibration curve. 
2.2.5 Evaluation Parameter of Reconstitutable Suspension 
2.2.5.1 Organoleptic property 
Prepared formulation with different excipient was observed 
for colour, odour and appearance and it was found properly mixed.  
2.2.5.2 pH 
The pH of reconstitutable suspension was determined by using 
digital pH meter (Welltonix digital pH meter PM100). 
2.2.5.3 Viscosity 
The viscosity of suspension was determined by Brookfield 
viscometer (Brookfield Eng. Lab). In adapter 40 ml of suspension was 
taken and the adapter is set over the viscometer by a stand such a way 
that spindle is completely immersed in the suspension. Spindle number 3 
was used. 
2.2.5.4 Sedimentation volume 
Take 10 ml of each suspension was taken in 50 ml stopper 
graduated measuring cylinder. The suspension was dispersed thoroughly 
by moving upside down for three times. Later, the suspension was 
allowed to settle for three minutes and the height of sediment was noted. 
This was the original height of sediment (H0). The cylinder was kept 
undisturbed for 7 days. The height of sediment read at every 24 hr for 7 
days was considered as final height of sediment (Hu). 
           Sedimentation volume (F) = Hu/H0 
The ultimate height of the solid phase after settling depends on 
concentration of solid content. To obtain an acceptable suspension, F 
should be at least 0.9 for 1hour but a longer period was preferred for our 
purpose and F value means sedimentation volume was measured to 
check the physical stability of the suspension. It can have values nearly 1. 
2.2.5.5 Redispersibility 
Fixed volume of each suspension (10 ml) was kept in 
stoppered cylinder which was stored at room temperature for 7 days. 
The redispersibility was determined by studying number of stocks to 
redisperse the formed sediment at the end of 7 days of storage of the 
formulation [19, 20]. 
2.2.5.6 Accelerator Stability Study 
The purpose of stability testing is to provide evidence on how 
the quality of drug substance or drug product varies with time under the 
 Sahilhusen I. Jethara et al/ Novel Oral Reconstitutable Sustained Release Suspension 
© ASD Publisher All rights reserved.                                                                                                                                                                                                                       4 
influence of a variety of environmental factors such as temperature, 
humidity, and light, and to establish a re-test for the drug substance or a 
shelf life for the drug product and recommended storage condition. The 
storage condition used for stability studies were accelerated condition 
400 C ± 20 C / 75 % ± 5% RH for the optimized formulation of 
reconstitutable sustained release suspension [21]. 
 
3. Result and discussion 
3.1 Drug Excipient Compatibility Study 
 
Fig. (1). Compatibility study of drug with excipients 
Fourier transform infrared spectroscopy has been used to 
study the physical and chemical interactions between drug and 
Excipients used in the formulation. Fourier transform infrared (FTIR) 
spectra of Linezolid, Eudragit RS100, Sucrose, Xanthan gum, citric acid 
and sodium benzoate were recorded using Potassium bromide (KBr) 
mixing method and there was not found any kind of interaction between 
drug, polymer and other excipient and it spectra of drug and excipient 
compatibility are showed in the Figure 1 and Table 6. 
Table 6: Functional Group and Frequency of Drug with Excipient 
Functional group Frequency  of Pure Drug (cm-1) 
C-H 680.89, 756.12 
R-CH=CH2 906.57 
N-H 1516 
C-N 1357 
C=O 1143.83, 1274.99 
 
FTIR peaks observed in the linezolid and excipient sample 
mixture were found to be 1274.99 cm-1, 1143.83 cm-1, 1357cm-1, 1516 
cm-1, 906.57 cm-1, 756.12 cm-1, 680.89 cm-1. 
3.2 Characterization of Microcapsule 
3.2.1 Physical Characterization of Microcapsule 
The angle of repose for the microcapsule was carried out after 
spray drying and results were reported that the batches F1, F2,F3,F6 has a 
value between 20° to 30°, which shows good flow property and batches F4, 
F5, F7, F8, and F9 shows range between 300 to 340, Which shows the 
passable flow property. 
Compressibility index for the microcapsule was carried out 
after spray drying and results were reported that the batches F1, F2, F5 
have a range between 11-15 so, it shows good compressibility index, 
batches F3, F4, F6, F7, F9 have a range between 16-20 so, it shows fair 
compressibility index and batches F8 have a range between 21-25 so, it 
shows the passable compressibility index. 
Hausner’s ratio for the microcapsule was carried out after 
spray drying and results were reported that the batches F1, F2, F3, F5 
have a range between 1.12-1.18 so, it shows good flow property, batches 
F4, F6, F7, F8, F9 have a range between 1.19-1.25 so, it shows a fair flow 
property. 
In the preliminary screening of the batches F1 to F9 have a 
physical characteristics of microcapsules in the acceptable range and all 
the result of Physical Characterization of Microcapsules of preliminary 
batches (F1-F9) are depicted in Table 7. 
 
Table 7: Physical Characterization of Microcapsule (F1-F9) 
Batch Bulk density (g/cm3) Tap density (g/cm3) Carr’s Index Hausner’s ratio Angle of repose 
F1 0.36 0.42 14.28 1.16 27.97 
F2 0.38 0.44 13.63 1.15 26.56 
F3 0.39 0.46 15.21 1.17 26.24 
F4 0.37 0.45 17.87 1.21 34.99 
F5 0.38 0.43 11.62 1.13 34.45 
F6 0.39 0.49 20.40 1.25 29.62 
F7 0.34 0.41 17.07 1.20 34.11 
F8 0.36 0.45 21.01 1.25 33.66 
F9 0.37 0.46 20.20 1.24 30.32 
 
3.2.2 Evaluation of Microcapsule 
In the preliminary study, the microcapsule batches were 
evaluated for % practical yield, encapsulation efficiency, % drug loading, 
mean particle size and surface morphology. The % practical yield, 
encapsulation efficiency and mean particle size are increased with 
increase to drug to polymer ratio and drug loading are decreased with 
increase to drug to polymer ratio. Hence, batch F3 show high % practical 
yield, encapsulation efficiency and particle size. Sustained release 
suspension was prepared for the 12 hours so, F1 batch are optimized for 
further factorial analysis with different polymer ratio and different feed 
flow rate (Table 8). 
 
Table 8: Evaluation of Microcapsule (F1-F9) 
Batch Practical yield (%) Drug loading (%) Encapsulation efficiency (%) Mean Particle Size (µm) 
F1 85.37 58.82 97.98 14.66 
F2 86 38.75 98.11 14.79 
F3 87 28.73 98.64 15.89 
F4 77.8 64.26 93.01 16.24 
F5 83.73 39.80 94.41 15.38 
F6 84.7 29.51 97.46 17.23 
F7 79 63 94.04 14.98 
F8 82 40.65 96.75 15.82 
F9 84 29.76 97.46 16.72 
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3.2.3 In-Vitro Drug Release of Preliminary Batches of Microcapsule 
In the present research work, formulation of preliminary 
batches F1 to F3 use Eudragit RS100 in varying concentration,  (1:1, 1:2, 
1:3)  for preparation of microcapsule by spray drying technique and it 
was reveal that as concentration of drug to polymer is increases with 
increase the drug release. F1 batches shows drug release up to 98.94 % 
within 10 hours whereas the formulation batches F2 and F3 shows the 
drug release up to 96.89 % and 83.98 % within 12 hours, respectively. 
Results were depicted in table 9 and figure 2. 
 
Table 9: In-Vitro Drug Release of Preliminary Batches (F1-F9) of Microcapsule. 
Time 
(Hours) 
CPR 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
1 36.88 23.75 22.55 47.89 39.09 36.18 36.08 35.75 33.47 
2 47.32 27.19 23.25 59.09 44.02 42.07 44.67 42.71 39.47 
3 57.42 35.99 27.31 61.07 53.66 49.44 53.61 47.24 43.79 
4 64.66 46.81 30.73 77.97 59.85 55.23 62.55 51.67 49.33 
5 76.96 53.45 34.40 86.97 63.51 59.11 73.28 58.46 55.99 
6 81.46 67.84 38.09 91.84 76.68 64.89 85.08 63.11 59.94 
7 87.80 74.95 46.48 98.89 79.66 67.81 91.49 69.55 64.45 
8 92.51 79.21 57.48  89.07 73.55 98.71 73.26 67.45 
9 97.21 83.78 66.67  91.02 77.61  77.41 73.31 
10 98.94 88.10 72.87  96.23 84.97  83.70 78.28 
11  93.83 76.77  98.91 89.80  87.29 83.68 
12  96.89 83.98   93.74  92.37 89.14 
 
In formulation batches F4 to F6 use the Eudragit RL100 in 
varying concentration, (1:1, 1:2 and 1:3) for preparation of microcapsule 
it was justify that as concentration of polymer is increases with increase 
the drug release. F4 batches shows drug release up to 98.89% within 7 
hours while the formulation batches F5 and F6 shows the drug release up 
to 98.91% and 93.74% within 11 and 12 hours, correspondingly. Results 
were depicted in table 9 and figure 2. 
In formulation batches F7 to F9 using ethyl cellulose in varying 
concentration, (1:1, 1:2 and 1:3) for preparation of microcapsule it was 
justify that as concentration of polymer is increases with increase the 
drug release. F7 batches shows drug release up to 98.71% within 8 hours 
even as the formulation batches F8 and F9 shows the drug release up to 
92.37% and 89.14%, in that order. Results were depicted in table 9 and 
figure 2. 
From all the batches of microcapsule (F1 to F9), F1 batch 
exhibit excellent and uniform drug release up to 98.94 % within 10hours, 
So Eudragit RS100 (1:1) ratio was use for optimization of flow rate.  
In the preliminary study other batches are also show drug 
release at 11 and 12 hours. Here F5 batches show drug release at the 11 
hours 98.91% but here drug to polymer ration are 1:2. So, finally bulky 
volume of reconstitutable suspension are increased and it not 
comfortable to the patient. 
Hence main goal to prepare reconstitutable sustained release 
suspension is, in the low drug to polymer ratio it give a sustained action 
till to 12 hours and it may too comfortable to the patient to take orally. 
So, here F1 batches are optimized for further factorial design to using 
1:1.1, 1:1.2 and 1:1.3 drug to polymer ratio and 5, 10, 15 ml/min feed 
flow rate. 
 
Fig. (2). CPR of the preliminary batches (F1-F9) batches 
This figure 2 indicates that with increase the drug to polymer ratio drug release rate are decreased. 
 
3.3 Evaluations of Factorial Batches of Microcapsule 
3.3.1 Physical characterization of factorial batches of Microcapsule 
Cars index of factorial batches are showed in the table 10. Here 
batches S1, S2, S3, S4, S5, S6 and S9 has a range between 11 to 15 so, it 
show good compressibility index and S7 and S8 has a range between 16 to 
20 so it show a fair compressibility index. 
Hausner’s ratio of factorial batches are showed in table 10 and 
here batches S1, S2, S3, S4, S5, S6, S7 and S9 has a range of hausner’s ratio 
between 1.2 to 1.8 so, it show a good flow property and batch S8 show a 
range between 1.19 to 1.25 so, it show a fair flow property. 
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Table 10: Physical characterization of factorial batches (S1-S9) 
Batch Bulk density (g/cm3) Tap density (g/cm3) Carr’s Index Hausner’s ratio Angle of repose Drug loading (%) 
S1 0.3816 0.4424 13.76 1.15 25.24 55.55 
S2 0.3848 0.4347 11.47 1.12 24.36 52.63 
S3 0.3875 0.4424 13.57 1.14 22.68 49.50 
S4 0.3787 0.4347 12.90 1.14 25.19 56.17 
S5 0.3848 0.4347 11.47 1.12 24.83 53.70 
S6 0.3921 0.4504 12.95 1.14 22.68 50.50 
S7 0.3636 0.4310 15.64 1.18 30.21 57.60 
S8 0.3676 0.4424 16.92 1.20 27.14 53.76 
S9 0.3737 0.4347 14.81 1.17 26.56 50.96 
 
Angle of repose of a factorial batches showed in the table 10. 
here batches S1, S2, S3, S4, S5, S6, S8 and S9 has a range of angle of repose 
between 20 to 30 so, it show a good flow property and batch S7 show a 
range between 30 to 34 so, it show a passable flow property. 
3.3.2 Evaluations of Factorial Batches of Microcapsule 
Ideal values of the percentage practical yield, percentage 
encapsulation efficiency and mean particle size are showed in the table 
11. The practical yields are increase with the increase the polymer ratio, 
but it may be decrease with increase the feed flow rate. But the 
percentage encapsulation efficiency is also increase with increase the 
polymer ratio, where as it may also decrease with increase the feed flow 
rate. Particle sizes of the factorial batches are increase with increase the 
polymer ratio and the feed flow rate. 
In present research work,S3 batch are optimized for 
preparation of the reconstitutable sustained release suspension because it 
has a high percentage yield (87.82) and percentage encapsulation 
efficiency (99.07), 16.06 µm mean particle size and smooth surface and 
spherical shape. 
Table 11: Evaluations of factorial batches of Microcapsule 
Batch Practical Yield (%) Encapsulation Efficiency (%) Mean Particle size(µm) Drug loading (%) 
S1 85.71 97.87 13.17 55.55 
S2 86.36 98.68 15.67 52.63 
S3 87.82 99.07 16.06 49.50 
S4 84.80 96.71 15.97 56.17 
S5 85.91 97.69 16.91 53.70 
S6 86.08 98.67 19.01 50.50 
S7 82.67 95.89 17.54 57.60 
S8 84.51 97.70 18.76 53.76 
S9 85.30 98.09 20.21 50.96 
3.3.3 In-Vitro Drug Release of Factorial Batches of Microcapsule 
In the factorial batches Eudragit RS 100 are used in the 
different concentrations with the different feed flow rate. In-vitro drug 
release profile of the factorial batches are showed in the table 12 and 
result indicate that drug release time are increased with increase the 
drug to polymer concentration and feed flow rate. From the study of 
factorial design, batch S3 are optimized for the preparation of 
reconstitutable suspension because it show maximum cumulative 
percentage drug release up to 99.12% within 12 hours as compare to 
other batches. 
Table 12: In-vitro drug release of factorial batches of Microcapsule 
Time (hrs) S1 S2 S3 S4 S5 S6 S7 S8 S9 
0 0 0 0 0 0 0 0 0 0 
1 41.58 38.76 36.35 40.34 37.25 35.67 39.75 37.34 35.09 
2 48.37 45.37 42.56 46.53 45.83 43.55 45.63 44.21 41.05 
3 56.42 51.78 48.33 54.35 52.64 47.35 50.64 49.67 46.53 
4 64.82 58.67 54.21 63.45 60.37 54.64 62.53 58.37 55.28 
5 71.89 66.31 60.45 71.53 67.25 63.64 70.46 64.86 61.48 
6 79.82 73.49 66.89 77.59 73.56 72.18 75.34 67.58 65.48 
7 87.35 81.64 73.09 82.69 79.38 77.68 80.45 72.58 69.87 
8 95.37 87.33 79.24 89.55 84.37 83.57 86.66 77.34 74.95 
9 98.64 93.86 85.11 94.36 91.65 89.08 93.56 83.49 79.32 
10  98.91 91.56 98.10 95.34 92.14 97.09 89.57 86.11 
11   95.89  98.34 94.53  92.67 89.46 
12   99.12   96.32  94.48 92.56 
 
 
Fig. (3). CPR of the factorial batches S1 to S9 
This figure 3 indicates that drug release rate are decreased with increase the drug to polymer ratio and feed flow rate. 
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3.3.4 Statistical Analysis of Factorial Batches 
All batches contained microcapsule which contains drug 
(linezolid) and polymer (Eudragit RS100) in a different ratio. In 32 full 
factorial design here takes independent variable X1 (polymer ratio like 
1:1.1, 1:1.2, 1:1.3) and X2 (feed flow rate 5, 10, 15 ml/min). A 32 full 
factorial design was designed to study the effects of the polymer ratio 
and feed flow rate (ml/min) of spray dryer on the percentage yield, mean 
particle size, encapsulation efficiency, Q6, Q8, t90, diffusion exponent (n) 
and release rate constant (k) of microcapsule. The result of analysis of 
variance test for all three effects indicated that the test is significant 
(Table 13).  
 
Table 13: Result of dependent variables 
Batch 
code 
Variable levels % 
Yield 
Mean Particle 
Size (µm) 
% Encapsulation    
Efficiency 
Q6 
(%) 
Q8 
(%) 
t90 
(hr) 
Diffusion 
Exponent (n) 
Release Rate 
constant (k) X1 X2 
S1 -1 -1 85.71 13.17 97.87 79.01 93.88 7.47 0.4159 0.3809 
S2 0 -1 86.36 15.67 98.68 73.04 86.79 8.465 0.428 0.349 
S3 1 -1 87.82 16.06 99.07 66.43 78.25 9.988 0.4317 0.3223 
S4 -1 0 84.80 15.97 96.71 75.85 89.71 8.040 0.4082 0.3715 
S5 0 0 85.91 16.91 97.69 71.44 83.18 8.999 0.4245 0.3483 
S6 1 0 86.08 19.01 98.67 68.91 79.64 9.766 0.441 0.3238 
S7 -1 1 82.67 17.54 95.89 69.96 81.41 9.49 0.3893 0.3627 
S8 0 1 84.51 18.76 97.70 66.69 77.26 10.40 0.3965 0.3444 
S9 1 1 85.30 20.21 98.09 63.78 74.34 10.96 0.4137 0.3194 
 
A statistical model incorporating interactive and poly nominal 
terms used to evaluate the response. 
Y =b0 + b1X1 + b2X2+ b11X1X1 + b22X2X2+ b12X1X2 
Where, Y is the dependent variable, b0 is the arithmetic mean 
response of 9 runs, and b1 is the estimated coefficients for the factor 
X1.The main effect (X1 and X2) represents the average result of changing 
one factor at a time from its low to high value. The interaction term 
(X1X2) shows how the responses changes when two factors are change 
simultaneously. The polynomial terms (X1X1, X2X2) are included to 
investigate nonlinearity.  
Analysis of variance (ANOVA) was performed to identify 
insignificant factors. Data were analyzed using Microsoft Excel software. 
The reduced models were developed for response variables by removing 
the insignificant terms with P more than 0.05. The terms with P less than 
0.05 were considered statistically significance and retained in the 
reduced model. 
3.4 Full and reduced model for % yield 
Y1 = 85.72+ 1.00X1- 1.23X2- 0.19X1X1- 0.20X2X2+ 0.13X1X2                           
Response plot indicate that the positive effect of polymer ratio 
on the percentage yield.  The response observed for this effect is of linear 
type. With increase in the polymer ratio, the percentage yield also 
increases due to the increase throughput of the polymer slurry and rapid 
evaporation of the solvent. Response surface plot also indicates the 
negative effect of feed flow rate on the percentage yield. The response 
observed for this effect is also of linear type. With increase in the feed 
flow rate, the value of percentage yield increases due to the incomplete 
atomization and drying, resulting in the deposition of a large amount of 
microcapsules on the walls of the desiccating chamber and the cyclone 
separator. 
The significance level of coefficients b11, b22and b12 was found 
to be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in table 14. The coefficients b1 and b2 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1 and b2 
contribute significant information for the prediction of % Yield. The 
results of testing the model in portions are shown in Table 15 and figure 
4. Polymer ratio at higher level (X1, +1) and feed flow rate at lower level 
(X2, -1) yielded microcapsules with higher percentage yield. 
Table 14: Summary of results of regression analysis for % Yield 
Response  % yield b0 b1 b2 b11 b22 b12 R2 P 
FM 85.72 1.00 -1.23 -0.19 -0.20 0.13 0.953 0.033 
P Value 1.84E-07 0.0163 0.0092 0.6188 0.6103 0.6409 - - 
RM 85.46 1.00 -1.23 - - - 0.939 0.00022 
 
Table 15: Calculation for testing the models in proportions for % Yield 
 DF SS MS F  
 
 
Fcal=0.2981 
Fcri= 9.2766 
(DF= 3,3) 
 
Regression 
FM 5 15.4177 3.083 12.187 
RM 2 15.191 7.595 46.252 
Residual 
FM 3 0.7590 0.2530 - 
RM 6 0.9853 0.1642 - 
 
 
Fig. (4). Response surface plot of % yield 
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3.5 Full and reduced model for Mean particle size (µm) 
Y2 = 17.37 + 1.43X1 + 1.93X2- 0.12X1X1 - 0.395X2X2- 0.055X1X2                 
When considering second response in term of particle size 
(Y2), interaction terms are insignificant. Response surface plot indicates 
the negative effect of drug to polymer ratio the particle size. The particle 
size of the microcapsule decreases with decrease the drug to polymer 
ratio or increase with increase the drug to polymer ratio and it may be 
increased due to increased viscosity of the feed solution which influence 
the interaction between disperse phase and dispersion medium that 
affects the size distribution of particle. 
Response surface plot indicates negative effects of feed flow 
rate. This may be due to a higher feed flow rate the atomizing air may not 
be able to penetrate the stream of liquid. As a result, incomplete 
atomization may lead to wider droplet size distribution.  
The significance level of coefficients b11, b22 and b12 was found 
to be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in Table 16. The coefficients b1 and b2were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1 and b2 
contribute significant information for the prediction of particle size (µm). 
The results of testing the model in portions are shown in Table 17 and 
figure 5. Drug to polymer ratio at lower level (X1, -1) and feed flow rate 
at lower level (X2, -1) yielded microcapsule with smaller particle size. 
 
Table 16: Summary of results of regression analysis for Mean particle size (µm) 
Response Particle size (µm) b0 b1 b2 b11 b22 b12 R2 P 
FM 17.37 1.43 1.93 -0.12 -0.395 -0.055 0.973 0.014 
P Value 3.19E-05 0.0085 0.0036 0.7847 0.3980 0.8588 - - 
RM 17.033 1.433 1.935 - - - 0.963 4.9E-05 
 
Table 17: Calculation for testing the models in proportions for Mean particle size (µm) 
 DF SS MS F  
 
 
Fcal=0.3643 
Fcri= 9.2766 
(DF= 3,3) 
 
Regression 
FM 5 35.144 7.028 21.765 
RM 2 34.792 17.396 78.966 
Residual 
FM 3 0.9688 0.3229 - 
RM 6 1.3217 0.2202 - 
 
 
Fig. (5). Response surface plot of Mean particle size 
3.6 Full and reduced model for Encapsulation efficiency (%) 
Y3 = 97.89+ 0.89X1- 0.656X2- 0.306X1X1 + 0.1933X2X2+ 0.25X1X2 
When considering the response term of encapsulation 
efficiency, the response surface plot indicates the positive effect of drug 
to polymer ratio on the response term. The encapsulation efficiency of 
the microcapsule increase with increase in the drug to polymer ratio, due 
to amount of drug remaining and available for encapsulation increases as 
theoretical drug loading increases. Consequently, the actual drug loading 
increases. As the molecular weight of the polymer increased, its 
hydrophobicity increased, leading to better precipitation of polymer at 
the boundary phase of the droplets. 
Response surface plot indicates negative effect of feed flow 
rate on the encapsulation efficiency; it may be due to that the high 
pumping rates during the spray drying process result in large volumes of 
nebulized solutions to be dried. Owing to this heated air may not 
instantaneously transform the liquid droplets into solid microcapsules, 
leading to the formation of larger, irregular particles that are not 
completely dried and hence resulting in decrease in encapsulation 
efficiency. The results of testing the model in portions are shown in Table 
18 and 19 and figure 6. Drug to polymer ratio at higher level (X1, +1) and 
feed flow rate at lower level (X2, -1) yielded microcapsule with higher 
percentage encapsulation efficiency. 
Table 18:  Summary of results of regression analysis for Encapsulation efficiency (%) 
Response Encapsulation efficiency (%) b0 b1 b2 b11 b22 b12 R2 P 
FM 97.89 0.89 -0.656 -0.306 0.1933 0.25 0.975 0.0012 
P Value 1.67E-08 0.0034 0.0083 0.1915 0.3672 0.1481 - - 
RM 97.81 0.893 -0.656 - - - 0.911 0.00068 
 
Table 19: Calculation for testing the models in proportions for Encapsulation efficiency (%) 
 DF SS MS F  
 
 
Fcal=2.566 
Fcri= 9.2766 
(DF= 3,3) 
 
Regression 
FM 5 7.888 1.577 23.675 
RM 2 7.375 3.6877 31.04 
Residual 
FM 3 0.199 0.0666 - 
RM 6 0.7127 0.1187 - 
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Fig. (6). Response surface plot of Encapsulation efficiency (%) 
 
3.7 Full and reduced model for the Q6 (%) 
Y4 = 71.88- 4.28X1- 3.00X2+ 0.266X1X1 - 2.24X2X2+ 1.6X1X2 
Here negative value of the X1(drug: polymer ratio) variable indicate that 
the Q6is decrease with respect to increase the polymer ratio.  
Here negative value of the X2(feed flow rate) variable indicate that the Q6 
is decrease with respect to increase the feed flow rate.  
When drug to polymer ratio and feed flow rate are increase, so 
there is increase size of particle and with respect to increase the particle 
size there is increase the time of cumulative percentage drug release with 
respect and According to Noyes Whitney equation the rate of dissolution 
is directly proportional to surface area of powdered drug that means 
higher surface area (very small the particle size), higher the rate of 
dissolution. If surface area of powdered drug is lower that means lower 
the rate of dissolution of powdered drug and higher the time of 
cumulative percentage drug release. Increase the particle size there is 
increase the time of drug release that means quantity of drug release is 
increase with increase in the drug to polymer ratio and feed flow rate. 
The results of testing the model in portions are shown in Table 20 and 21 
and figure 7. 
Table 20: Summary of results of regression analysis for Q6 (%) 
Response Q6 (%) b0 b1 b2 b11 b22 b12 R2 P 
FM 71.88 -4.28 -3.00 0.266 -2.24 1.6 0.986 0.005 
P Value 1.89E-06 0.0014 0.0040 0.708 0.040 0.039   
RM 72.06 -4.283 -3.00 - -2.248 1.6 0.985 0.0006 
 
Table 21: Calculation for testing the models in proportions for Q6 (%) 
 DF SS MS F  
 
Fcal=0.169 
Fcri= 10.12 
(DF= 1,3) 
 
Regression 
FM 5 184 36.97 43.99 
RM 4 184.73 46.18 69.35 
Residual 
FM 3 2.512 0.840  
RM 4 2.663 0.66  
 
 
Fig. (7). Response surface plot of the Q6 (%) 
                   
3.8 Full and reduced model for the Q8 (%) 
Y5 = 83.86- 5.46X1- 4.31X2+ 0.46X1X1 - 2.18X2X2+ 2.14X1X2 
Here negative value of the X1(drug: polymer ratio) variable indicate that 
the Q8 is decrease with respect to increase the polymer ratio.  
Here negative value of the X2(feed flow rate) variable indicate that the Q8 
is decrease with respect to increase the feed flow rate.  
When drug to polymer ratio and feed flow rate are increase, so 
there is increase size of particle and with respect to increase the particle 
size there is increase the time of cumulative percentage drug release with 
respect and According to Noyes Whitney equation the rate of dissolution 
is directly proportional to surface area of powdered drug that means 
higher surface area (very small the particle size), higher the rate of 
dissolution. If surface area of powdered drug is lower that means lower 
the rate of dissolution of powdered drug and higher the time of 
cumulative percentage drug release. Increase the particle size there is 
increase the time of drug release that means quantity of drug release is 
increase with increase in the drug to polymer ratio and feed flow rate. The 
results of testing the model in portions are shown in Table 22 and 23 and 
figure 8. 
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Table 22: Summary of results of regression analysis for Q8 (%) 
Response Q8 (%) b0 b1 b2 b11 b22 b12 R2 P 
FM 83.86 -5.46 -4.31 0.46 -2.18 2.14 0.993 0.0019 
P Value 9.8E-07 0.0005 0.0011 0.502 0.036 0.015 - - 
RM 84.17 -5.46 -4.318 - -2.18 2.14 0.991 0.000201 
 
Table 23: Calculation for testing the models in proportions for Q8 (%) 
 DF SS MS F  
 
 
Fcal=0.578 
Fcri= 10.12 
(DF= 1,3) 
 
Regression 
FM 5 319.18 63.83 86.56 
RM 4 318.76 79.69 120.80 
Residual 
FM 3 2.212 0.7374  
RM 4 2.63 0.6596  
 
 
Fig. (8). Response surface plot of the Q8 (%) 
 
3.9 Full and reduced model for the t90 (hr) 
Y6 = 8.93 + 0.950X1 + 0.823X2- 0.001X1X1 + 0.531X2X2- 0.260X1X2 
Here positive value of the X1(drug: polymer ratio) variable indicate that 
the t90 (hr) is increase with respect to increase the polymer ratio.  
Here positive value of the X2(feed flow rate) variable indicate that the t90 
(hr) is increase with respect to increase the feed flow rate. 
When drug to polymer ratio and feed flow rate are increase, so there is 
increase size of particle and with respect to increase the particle size 
there is increase the time of cumulative percentage drug release with 
respect and According to Noyes Whitney equation the rate of dissolution 
is directly proportional to surface area of powdered drug that means 
higher surface area (very small the particle size), higher the rate of 
dissolution. If surface area of powdered drug is lower that means lower 
the rate of dissolution of powdered drug and higher the time of 
cumulative percentage drug release. Increase the particle size there is 
increase the time of drug release that means quantity of drug release is 
increase with increase in the drug to polymer ratio and feed flow rate. The 
results of testing the model in portions are shown in Table 24 and 25 and 
figure 9.  
Table 24: Summary of results of regression analysis for t90 (hr) 
Response t90 (hr) b0 b1 b2 b11 b22 b12 R2 P 
FM 8.93 0.950 0.823 -0.001 0.531 -0.2607 0.990 0.0030 
P Value 7.5E-06 0.0010 0.0015 0.9912 0.025 0.062   
RM 8.935 0.9504 0.8236 - 0.5319 -0.260 0.990 0.00026 
 
Table 25: Calculation for testing the models in proportions for t90 (hr) 
 DF SS MS F  
 
 
Fcal=7.044E-05 
Fcri= 10.12 
(DF= 1,3) 
 
Regression 
FM 5 10.32 2.065 63.48 
RM 4 10.32 2.58 105.80 
Residual 
FM 3 0.0976 0.3253  
RM 4 0.0976 0.0244  
 
 
Fig. (9). Response surface plot of the t90 (hr) 
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3.10 Full and reduced model for the diffusion exponent (n) 
Y7= 0.4243+ 0.012X1- 0.012X2+ 0.0003X1X1 - 0.012X2X2+ 0.00215X1X2 
Here positive of the X1(drug: polymer ratio) variable indicate that the 
diffusion constant is increase with respect to increase the polymer ratio.  
Here negative value of the X2(feed flow rate) variable indicate that the 
diffusion constant is decrease with respect to increase the feed flow rate.  
The significance level of coefficients b11 and b12 was found to 
be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in table 26. The coefficients b1, b2 and b22 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1, b2 and b22 
contribute significant information for the prediction of diffusion 
exponent (n). The results of testing the model in portions are shown in 
Table 27. The critical value of F for α = 0.05 is equal to (DF=2, 3). Since 
the calculated value (F=0.341) is less than the critical value (F=9.55), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of diffusion exponent (n). The results are shown in the 
form of response surface plot in figure 10. 
Table 26: Summary of results of regression analysis for diffusion exponent (n) 
Response  diffusion exponent (n) b0 b1 b2 b11 b22 b12 R2 P 
FM 0.4243 0.012 -0.01 0.0003 -0.012 0.00215 0.963 0.0229 
P Value 1.71E-06 0.0107 0.009 0.940 0.0471 0.4711   
RM 0.4245 0.012 -0.01 - -0.012 - 0.955 0.00085 
 
Table 27: Calculation for testing the models in proportions for diffusion exponent (n) 
 DF SS MS F  
 
 
Fcal=0.341 
Fcri= 9.55 
(DF= 2,3) 
 
Regression 
FM 5 0.0021 0.00043 15.81 
RM 3 0.0021 0.00071 35.48 
Residual 
FM 3 8.2E-05 2.73E-05  
RM 5 0.00010 2.01E-05  
 
 
Fig. (10). Response surface plot of the diffusion exponent (n) 
3.11 Full and reduced model for the release rate constant (k) 
Y8 = 0.3481- 0.024X1- 0.004X2- 0.0004X1X1 - 0.0014X2X2+ 
0.0038X1X2 
Here negative value of the X1(drug: polymer ratio) variable 
indicate that the release rate constant is decrease with respect to increase 
the polymer ratio.  
Here negative value of the X2(feed flow rate) variable indicate 
that the release rate constant is decrease with respect to increase the feed 
flow rate.  
The significance level of coefficients b11 and b22 was found to 
be greater than P=0.05, thus they were omitted from the full model to 
generate the reduced model. The results of statistical analysis are shown 
in table 28. The coefficients b1, b2 and b12 were found to be significant at P 
<0.05, thus they were retained in the reduced model. The reduced model 
was tested in portions to determine whether the coefficients b1, b2 and b12 
contribute significant information for the prediction of release rate 
constant (k). The results of testing the model in portions are shown in 
Table 29. The critical value of F for α = 0.05 is equal to (DF=2, 3). Since 
the calculated value (F=0.434) is less than the critical value (F=9.55), it 
may be concluded that the omitted term do not contribute significantly to 
the prediction of release rate constant (k). The results are shown in the 
form of response surface plot in figure 11. 
Table 28: Summary of results of regression analysis for release rate constant (k) 
Response release rate constant (k) b0 b1 b2 b11 b22 b12 R2 P 
FM 0.3481 -0.024 -0.004 -0.0004 -0.0014 0.0038 0.996 0.0008 
p Value 2.51E-07 0.0001 0.0188 0.789 0.441 0.043 - - 
RM 0.3469 -0.024 -0.004 - - 0.003 0.994 3.69E-06 
 
Table 29: Calculation for testing the models in proportions for release rate constant (k) 
 DF SS MS F  
 
 
Fcal=0.434 
Fcri= 9.55 
(DF= 2,3) 
 
Regression 
FM 5 0.0039 0.00078 152.511 
RM 3 0.0038 0.0013 328.08 
Residual 
FM 3 1.54E-06 5.12E-06  
RM 5 1.98E-05 3.96E-06  
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Fig. (11). Response surface plot of release rate constant (k) 
 
3.12 Kinetic Modeling of Dissolution Data 
The kinetics of the dissolution data were well fitted to zero 
order, Higuchi model and Korsemeyer-Peppas model as evident from 
regression coefficients (table 30). The value of diffusion exponent (n) for 
S1 to S9 factorial formulations was between 0.3585 to 0.4317 so it 
indicates Fickian diffusion of the drug from formulation which 
corresponds to diffusion, erosion and swelling mechanism. Kinetic model 
Higuchi indicating that R2 value of S1 to S9 was between 0.981 to 0.998 
shows that drug release type was diffusion type from gel network and 
extended drug release for longer period of time. Kinetic Model Zero order 
indicating that R2 value of S1 to S9 was in range 0.981 to 0.999 that near 
about 1.000 clearly mentioned that drug release from stiff gel networking 
was Zero order drug release that not depend on concentration of drug. 
Kinetic Model First order indicating that R2 value of S1 to S9 was between 
0.956 to 0.986 that having less than Zero order release R2 value, 
mentioned that drug release type was not first order release from gel 
network (Table 30). 
Table 30: Kinetic Modeling of Dissolution Data 
Parameters S1 S2 S3 S4 S5 S6 S7 S8 S9 
Zero order 
S 7.529 6.71 5.90 7.18 6.11 5.54 5.48 4.81 4.80 
I 36.56 35.44 30.98 39.32 36.01 36.60 37.49 36.50 34.31 
R2 0.998 0.991 0.998 0.984 0.992 0.981 0.998 0.995 0.995 
First order 
S 0.047 0.043 0.0394 0.044 0.039 0.036 0.035 0.032 0.033 
I 1.61 1.600 1.564 1.638 1.607 1.606 1.621 1.604 1.580 
R2 0.971 0.967 0.986 0.967 0.972 0.956 0.989 0.978 0.977 
Higuchi 
S 30.98 28.89 27.06 29.66 27.28 5.546 24.16 22.23 22.17 
I 7.750 7.442 3.42 11.62 8.72 36.60 13.73 13.59 11.46 
R2 0.994 0.998 0.990 0.994 0.996 0.981 0.990 0.996 0.996 
Hixon Crowell 
S -2.50 -2.23 -1.96 -2.395 -2.036 -1.84 -1.827 -1.605 -1.600 
I 21.14 21.51 23.00 20.22 21.32 21.13 20.83 21.16 21.89 
R2 -0.98 -0.991 -0.998 -0.984 0.992 -0.981 -0.998 -0.995 -0.995 
Korsemeyer and Peppas 
N 0.424 0.428 0.431 0.400 0.411 0.414 0.358 0.363 0.376 
I -0.40 -0.439 -0.491 -0.386 -0.440 -0.456 -0.414 -0.446 -0.471 
R2 0.991 0.995 0.982 0.991 0.992 0.990 0.981 0.990 0.990 
S= slope, I= intercept, R2= square of correlation coefficient, n= diffusion exponent 
 
3.13 Comparison of Dissolution Profiles For Selection of Optimum 
Batch 
The values of Dissimilarity factor (f1) for batches S2, S3, S5, S6, 
S7, S8, and S9 were less than 15 compared with theoretical dissolution 
profile indicating good similarity in dissolution. The batch S3 showed 
minimum value of f1 (2.90). The values of similarity factor (f2) for batches 
S2, S3, S5, S6, S7, S8, and S9 were greater than 50 compared with 
theoretical dissolution profile indicating good similarity in dissolution. 
The batch S3 showed maximum value of f2 (82.35). Similarity Factor (f2) 
and Dissimilarity factor (f1) for S1-S10 are showed in table 31. 
Table 31: Similarity Factor (f2) and Dissimilarity factor (f1) for S1-S9 
Batch Similarity factor (f2) Dissimilarity factor (f1) 
S1 44.56 21.85 
S2 54.50 12.83 
S3 82.35 2.90 
S4 49.71 16.46 
S5 57.93 10.54 
S6 66.62 5.75 
S7 62.79 8.25 
S8 73.32 4.315 
S9 75.92 3.18 
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3.14 Validation of Experimental Design 
1. Percentage relative error or bias 
Reliability of the generated models was studied by comparing 
the experimental and predicted values in terms of % bias. Low values of 
% bias for all responses shows a good agreement between the 
experimental and predicted values (Table 32, 33 and 34). The result of 
analysis of variance test for both effects indicated that the test is 
significant. 
Table 32: Actual response, predicted response and % bias obtained for the studied parameters percentage yield, mean particle size, 
encapsulation efficiency 
Code % Yield Mean particle size % Encapsulation efficiency 
Predicted Actual % Bias Predicted Actual % Bias Predicted Actual % Bias 
S1 85.69 85.71 0.02 13.44 13.17 2.00 97.79 97.87 0.08 
S2 84.29 86.36 2.45 15.04 15.67 4.18 98.73 98.68 0.05 
S3 87.69 87.82 0.14 16.41 16.06 2.13 97.76 99.07 1.34 
S4 84.53 84.80 0.31 15.82 15.97 0.94 96.88 96.71 0.17 
S5 85.72 85.91 0.22 17.37 16.91 2.64 97.89 97.69 0.20 
S6 88.53 86.08 2.76 18.68 19.01 1.76 98.47 98.67 0.20 
S7 85.43 82.67 3.23 17.41 17.54 0.74 95.92 95.89 0.03 
S8 84.29 84.51 0.26 18.90 18.76 0.74 97.42 97.70 0.287 
S9 85.23 85.30 0.08 20.16 20.21 0.24 98.26 98.09 0.17 
Table 33:  Actual response, predicted response and % bias obtained for the studied parameters Q6, Q8, t90 
Code Q6 (%) Q8 (%) t90(hr) 
Predicted Actual % Bias Predicted Actual % Bias Predicted Actual % Bias 
S1 78.78 79.01 0.29 94.05 93.88 0.18 7.42 7.47 0.67 
S2 69.64 73.04 4.88 85.99 86.79 0.93 8.63 8.465 1.96 
S3 67.02 66.43 0.88 78.85 78.25 0.76 9.84 9.988 1.42 
S4 76.42 75.85 0.74 89.78 89.71 0.07 7.97 8.040 0.87 
S5 71.88 71.44 0.61 83.86 83.18 0.81 8.93 8.999 0.67 
S6 67.86 68.91 1.54 78.86 79.64 0.98 9.87 9.766 1.11 
S7 69.58 69.96 0.54 81.15 81.41 0.32 9.59 9.49 1.04 
S8 66.64 66.69 0.07 77.37 77.26 0.14 10.28 10.40 1.16 
S9 64.22 63.78 0.68 74.51 74.34 0.22 10.97 10.96 0.09 
Table 34: Actual response, predicted response and % bias obtained for the studied parameters Diffusion Exponent (n) and Release Rate 
constant (k) 
Code Diffusion Exponent (n) Release Rate constant (k) 
Predicted Actual % Bias Predicted Actual % Bias 
S1 0.4147 0.4159 0.289 0.3781 0.3809 0.74 
S2 0.4243 0.428 0.87 0.3507 0.349 0.48 
S3 0.4344 0.4317 0.62 0.3225 0.3223 0.06 
S4 0.4126 0.4082 1.06 0.3717 0.3715 0.05 
S5 0.4243 0.4245 0.04 0.3481 0.3483 0.05 
S6 0.4366 0.441 1.00 0.3237 0.3238 0.03 
S7 0.3864 0.3893 0.75 0.3701 0.3627 1.99 
S8 0.4003 0.3965 0.94 0.3427 0.3444 0.379 
S9 0.4147 0.4137 0.24 0.3221 0.3194 0.83 
 
2. Check point batch  
The 32 factorial designs were run with one check point 
composition of which is shown in Table 35. Batch CP1 was prepared to 
validate the derived equation for Evaluation parameter and in-vitro 
dissolution time of microcapsule with one check point composition. The 
data for Evaluation parameter and in vitro dissolution time for the 
predicted and observed values are shown in table 35. 
It can be observed that the predicted value and observed value 
for CP1 for Evaluation parameter and in-vitro dissolution time of 
microcapsule were nearly similar with 32 factorial designs batches. It can 
be concluded that the evolved model can be used for prediction of 
response i.e. Evaluation parameter and in-vitro dissolution time of 
microcapsule within the simplex space. Comparative analysis of the 
predicted value and experimental value using paired t– test indicated 
that there was no significant difference between the two values thereby 
establishing validity of generated mode. In this research work between 
the tstat (1.36) and tcri (2.44) not significant difference and tcri value very 
high as compare to tstat. 
In the present research work, no very much difference 
between factorial batches and one check point composition and 
percentage relative error small between predicted and experimental 
value. 
Table 35:  Composition and Evaluation parameter and in-vitro dissolution of check point batch 
Check point batch (CP1) 
Evaluation parameter 
% yield Mean particle size % Encapsulation efficiency 
P O P O P O 
X1 = -0.5; X2 = +0.5; X3 =7.5 84.5 84.6 17.5 18.1 97.02 96.31 
Check point batch (CP1) 
In-vitro dissolution study 
Q6 Q8 t90 
P O P O P O 
X1 = -0.5; X2 = +0.5; X3 =7.5 71.95 67.41 83.98 78.83 9.1 9.95 
Check point batch (CP1) 
In-vitro dissolution study 
Exponential constant (n) Release rate constant (k) 
P O P O 
X1 = -0.5; X2 = +0.5; X3 =7.5 0.4249 0.4248 0.3467 0.3300 
* P= Predicted value; O = Observed value 
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3.15 Morphological Studies of Microcapsules 
 By simple microscope 
The surface topography of the microcapsule was investigated by 
simple binocular microscope. As seen in figure 12, they were spherical in 
shape and exhibited porous surface. 
 
Fig. (12). Morphological Characteristics of Microcapule by simple 
microscope 
 
 SEM analysis of the microcapsule 
SEM of drugs loaded polymeric microcapsule reveals that the 
microcapsule possess rough, porous and rugged surface Figure 13. The 
surface porosity is crucial for drug release in microcapsule prepared, 
since the polymer is not biodegradable, the release of the drugs from 
microcapsule take place by dissolution and diffusion through the pores. 
The most part of microcapsule was small and had spherical shape, non-
uniform surface and were coalesced.                        
 
Fig. (13). SEM analysis of the microcapsule 
Evaluation of Reconstitutable Suspension 
1. In-vitro dissolution study 
Reconstitutable suspension are prepared by using a various 
suspending agent like xanthan gum, acacia and guar gum and here 
suspending agent do not have a more effect of the drug release profile of 
the reconstitutable SR suspension. In the batches no N1-N3 there is use a 
xanthan gum (2, 3, 4 % w/w), N4-N6 uses acacia (2, 3, 4 % w/w) and in 
N7-N9 uses a gaur gum (2, 3, 4 % w/w) respectively (Table 36).  
Table 36:  Dissolution profile of Reconstitutable suspension 
Time (hrs) N1 N2 N3 N4 N5 N6 N7 N8 N9 
0 0 0 0 0 0 0 0 0 0 
1 37.04 35.67 34.21 36.91 36.67 35.76 37.79 36.46 38.76 
2 42.34 40.98 39.83 40.64 45.25 43.68 41.35 42.44 43.68 
3 47.55 47.69 43.65 44.61 51.73 47.56 44.51 49.21 48.56 
4 55.64 53.45 51.93 48.53 58.39 53.51 48.94 54.29 54.51 
5 61.09 59.15 59.86 53.82 62.37 59.41 53.34 62.13 59.58 
6 67.88 65.32 64.72 59.18 66.58 65.77 61.89 68.49 64.77 
7 72.49 72.42 71.86 64.32 72.86 71.53 69.44 74.59 70.37 
8 78.91 78.64 76.53 72.56 77.56 76.52 77.61 78.64 76.81 
9 86.47 84.39 82.14 81.86 83.67 84.61 82.81 85.46 82.89 
10 90.55 90.79 87.64 89.43 89.46 93.82 89.75 92.58 92.56 
11 96.18 93.85 92.58 95.46 95.47 97.67 94.81 96.33 95.46 
12 98.71 98.34 98.15 98.23 98.11 98.07 98.43 98.31 98.11 
 
2. Organoleptic property of all formulation 
 Colour- White 
 Odour- odourless 
 Appearance –white amorphous dry mixture  
 Flavor- cherry flavor 
 
 
3. Sedimentation volume 
The sedimentation volumes of all the formulations are 
depicted in table 37. F value means sedimentation volume was measured 
to check the physical stability of the suspension. It can have values nearly 
1. The result showed that formulation batch (N3) having sedimentation 
of(0.928) after 7 days which is very nearer to the standard value of 
sedimentation volume 1, so that N3 formulation was better than other. 
 
Table 37:  Sedimentation rate of the reconstitutable suspension 
 
 
Formulations 
Height of sediment(cm) after Sedimentation 
Volume 
F = Hu/Ho 
 
Ho 
1 
Day (Hu) 
2 
Day (Hu) 
3 
Day (Hu) 
4 
Day (Hu) 
5 
Day (Hu) 
6 
Day (Hu) 
7 
Day 
(Hu) 
N1 7.0 6.7 6.6 6.5 6.5 6.4 6.3 6.2 0.885 
N2 7.0 6.8 6.7 6.6 6.5 6.4 6.4 6.3 0.900 
N3 7.0 6.8 6.7 6.7 6.6 6.6 6.5 6.5 0.928 
N4 7.0 6.5 6.4 6.3 6.2 5.9 5.8 5.7 0.814 
N5 7.0 6.6 6.5 6.4 6.4 6.2 6.0 5.9 0.842 
N6 7.0 6.7 6.6 6.5 6.4 6.3 6.3 6.2 0.885 
N7 7.0 6.1 5.8 5.7 5.5 5.2 4.9 4.7 0.671 
N8 7.0 6.2 6.0 5.8 5.6 5.4 5.1 4.9 0.700 
N9 7.0 6.4 6.2 6.1 5.9 5.8 5.8 5.7 0.814 
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4. pH 
The pH of reconstitutable suspension was determined by using 
digital pH meter (Welltonix digital pH meter PM100). All the batches N1-
N9 have a pH 7.0, which are neutral and it is show in the table 38. 
5. Viscosity 
Viscosity of different formulation is shown in table 38. Xanthan 
gum imparts its high viscosity at low concentration with good ranging 
flow characteristics, which increase with increasing concentration of 
suspending agent. In this formulation batch N3 has a high viscosity (697 
cP) as compare to other batches.  
6. Redispersibility 
The Redispersibility of preliminary batches of reconstituted 
suspension is exhibited in table 38. Redispersibility is an important factor 
when one has to deal with suspension. As if there is no dispersion of 
suspension then it will lead to caching of solid content and if caking 
occurs then there must be chance of non-uniform dose of drug during 
medication because the drug remains in the cake. Result shows 
formulation batch N3 had minimum number of strokes 4 as compared to 
other formulation batch. 
 
Table 38:  Viscosity, pH and Redispersibility of the reconstitutable 
suspension 
Batch No. Viscosity (cP) pH Redispersibility  
(No. of Strokes) 
N1 672 7.0 7 
N2 683 7.0 5 
N3 697 7.0 4 
N4 657 7.0 7 
N5 664 7.0 6 
N6 671 7.0 5 
N7 623 7.0 8 
N8 631 7.0 7 
N9 636 7.0 6 
 
Accelerator Stability Studies of Reconstitutable Sustained Release 
Suspension 
Result showed accelerator stability parameter of the prepared 
formulation batch N3 is depicted in table 39. To obtain acceptable 
suspension, all parameter have minor differences. 
 
Table 39: Accelerator stability studies of the reconstitutable 
suspension 
Evaluation Parameters Initial After 15 days 
Colour White White 
Odour Cherry Cherry 
pH 7.0 6.8 
Sedimentation volume 7.0 6.3 
Viscosity 697 703 
Redispersibility 4 6 
% Drug Release 98.15 96.84 
 
4. Conclusion 
In the present Research work, attempt has been made to 
design and develop reconstitutable sustained release (SR) suspension of 
linezolid using spray drying technique for decrease the dosing frequency 
and suitable for pediatric and geriatric patients. 
Spray drying technique are used to prepare microcapsule for 
reconstitutable SR suspension of API (linezolid) and polymer (Eudragit 
RS100, Eudragit RL100 and Surelease), which are freely soluble in the 
dichloromethane so it is used as a solvent to prepare microcapsule in the 
preliminary and factorial batches.  
From the preliminary study, Eudragit RS100 was exhibited the 
higher % practical Yield, more encapsulation efficiency, superior mean 
particle size, uniform drug release for prolong period up to 10 hrs. So, 
batch F1 are more suitable and used for the preparation further 32 
factorial batches.  
FTIR spectroscopy revealed that there was no chemical 
interaction between drug and polymer so; it is compatible with drug and 
polymers. Scanning electron Microscopy showed that microcapsules 
were spherical with smooth surface. 
Results was clearly indicated that drug to polymer ratio and 
feed flow rate had significant influence on percentage yield, mean 
particle size, encapsulation efficiency, Q6, Q8, t90, Diffusion coefficient (n) 
and Release rate constant (k). Form the study, the optimized formulation 
(S3) showed 99.12% cumulative drug release at the end of 12 hrs with 
drug to polymer ratio (1:1.3) and feed flow rate (5 ml/min) respectively 
for obtaining the higher percentage of yield, maximum encapsulation 
efficiency, Particle size of microcapsules which is found to be 87.82%, 
99.07% and 16.06µm consequently. 
In 32 factorial designs batches were used two independent 
variable X1(drug to polymer ratio) and X2 (feed flow rate), while 
percentage yield, mean particle size, encapsulation efficiency, Q6, Q8, t90, 
Diffusion coefficient (n) and Release rate constant (k) were taken as 
dependent variable and in the 32 factorial designs the positive coefficient 
of X1 in case Y1,Y2, Y3, Y6 and Y7 refers to increase in percentage yield, 
particle size, encapsulation efficiency,t90 and diffusion exponent (n) with 
increase in drug to polymer ratio. Similarly, positive coefficient of X2 in 
case of Y2 and Y6 refers to increase mean particle size and t90 with 
increase in feed flow rate.  
While in case of response term Y4, Y5 and Y8, there is negative 
coefficient of X1 refers to decrease in Q6,Q8 and release rate constant (k) 
with increase to drug to polymer ratio. Whereas,  In case of response 
term Y3, Y4, Y5, Y7 and Y8, there is negative coefficient of X2 refers to 
decrease in encapsulation efficiency, Q6, Q8, diffusion exponent (n) and 
release rate constant (k) with increase to drug to polymer ratio. 
Low values of % bias for all responses shows a good 
agreement between the experimental and predicted values. Comparative 
analysis of the predicted value and experimental value using paired t – 
test indicated that there was no significant difference between the two 
values thereby establishing validity of generated mode of Evaluation 
parameter and in-vitro dissolution time of microcapsule with one check 
point composition. The results from the estimated ridge of maximum 
response value of Y1 (percentage yield), minimum response value of Y2 
(particle size) and maximum response value of Y3 (Encapsulation 
efficiency) and cumulative percentage drug release  in terms of 
desirability revealed that optimum drug to polymer ratio (X1) and feed 
flow rate (X2) were 1:1.3 and 5 ml/min respectively are desirable.  
From the full factorial design and different graphical 
representation, it was finalized that batch S3 was found to be optimized 
batch having drug release up to 12 hr. More ever, the dissolution profile 
of optimized batch S3 was found to be similar with theoretical drug 
release profile having similarity factor more than 50 (f2= 82.35) and 
dissimilarity factor less than 15 (f1=2.90) which reflects the feasibility of 
the optimization procedure in successful development of sustained 
release microcapsule by using Eudragit RS 100. 
Microcapsule prepared with 1:1.3 drug to polymer ratio were 
selected for SR suspension formulations since they have higher loading 
efficiency and suitable micrometric properties to disperse in aqueous 
medium. Reconstitutable SR suspensions were prepared using optimize 
batch of microcapsules with various suspending agent (xanthan gum, 
acacia, gaur gum), Sweetener (sucrose), preservative (Na benzoate), 
buffering agent (citric acid) and flavoring agent (cherry). 
From the results of reconstitutable SR suspension, it can 
conclude that the high sedimentation volume and better redispersibility 
and high viscosity of the suspending agent xanthan gum in a low quantity 
which more suitable for the optimization of formulation.  
As the viscosity of suspension was higher the particles or solid 
contents present in the suspension will not sediment for a longer time. So 
they will remain suspended in the suspension. Due to this effect the 
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sedimentation volume of suspension was higher and the sedimentation 
rate was slow.  
Redispersibility of higher viscous suspension is also better. 
This was because of that as the lowest sediments of particles occur it will 
easily redisperse again. So in present work it was shown that due to high 
viscosity of xanthan gum (3% w/w), it’s the sedimentation volume was 
highest and redispersibility and viscosity was better than  other 
formulations. 
Results clearly revealed that drug release studies of SR 
suspension formulation did not show any statistically significant 
differences (P>0.05) from the properties of microcapsule alone. 
Results reported the release profiles of suspension prepared 
from microcapsules no significant difference (P>0.05) was observed in 
cumulative percentage drug release for sustained release suspension on 
1day and after 15days which indicates the suspension stability. 
Finally, it was concluded that the type of polymer and feed 
solution of the spray dryer had a major impact on the in vitro release of 
drug from microcapsules and suspensions and it can be precise dosing of 
drug, patient compliance  and suitable for pediatric and geriatric 
intended sustained release of drug up to 12 hrs. 
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